Mortality after CABG versus PCIIndividual patient-data pooled analysis of 11,518 patients from 11 randomized trials

Stuart Head and Pieter Kappetein

Dept Cardio-thoracic Surgery Erasmus University Medical Center Rotterdam, The Netherlands

On behalf of:

Milan Milojevic, MD, MSc¹ Joost Daemen, MD PhD; Jung-Min Ahn, MD; Professor Eric Boersma, PhD²; Evald H. Christiansen, MD PhD⁴; Professor Michael J. Domanski, MD^{5, 6}; Michael E. Farkouh, MD PhD^{5, 6}; Professor Marcus Flather, MD PhD⁷; Valentin Fuster, MD, PhD⁵; Grigorios Papageorgiou, MSc^{1, 8}; Niels R. Holm, MD⁴; Professor Mark A. Hlatky, MD⁹; Whady A. Hueb, MD^{1b}; Masoor Kamalesh, MD¹¹; Young-Hak Kim, MD³; Timo Mäkikallio, MD¹²; Professor Friedrich W. Mohr, MD PhD¹³; Seung-Jung Park, MD³; Alfredo E. Rodriguez, MD PhD¹⁴; Joseph F. Sabik III, MD¹⁵; Rodney H. Stables, MD¹⁶; Gregg W. Stone, MD; Professor Patrick W. Serruys, MD PhD





Disclosure Statement of Financial Interest

Within the past 12 months, I or my spouse/partner have had a financial interest/arrangement or affiliation with the organization(s) listed below.

Affiliation/Financial Relationship

Employee

- Company
- Medtronic







Numerous trial have compared CABG and PCI

Multi-vessel disease

Left Main disease







No studies have been powered to detect a difference in Mortality or Stroke







Patients



Baseline Characteristics

	PCI (n=5753)	CABG (n=5765)
Age	64 ± 9·8	64 ± 9.9
Female sex	24%	24%
Diabetes	39%	38%
Insulin treated	13%	12%
Previous TIA or CVA	5%	6%
Previous MI	28%	28%
Moderate LVEF (30-49%)	15%	14%
Poor LVEF (<30%)	1%	1%
Three-vessel disease	59%	61%
Left main disease	39%	39%





Procedure Characteristics

PCI – stents*		-
BMS	27%	-
DES	73%	_
First-generation DES	39%	-
Newer-generation DES	34%	-
PCI – number of stents	3•1 ± 2•	0 -
CABG = LIMA use	-	96%
CABG – BIMA use	-	19%
CABG – off-pump	-	28%






Mortality Results

5 year overall


† PCI: 11·2%	
† CABG: 9.2%	→P=0.0038
† PCI: 11·5%	
† CABG: 8⋅9%	→ P=0.0019
† PCI: 10·7%	
† CABG: 10·5%	→ P=0.52

Overall Mortality PCI versus CABG



t2017







Subgroup analysis


isk Male 387/4380 (10-7) 318/4394 (8-8) 1-20 (1-031-33) 0.0181 0.42 Female 152/1373 (12-7) 119/1371 (10-6) 1-23 (10-97-157) 0.0854 0.98 465 200/2971 (8-0) 160/2940 (6-4) 1-23 (10-01-51) 0.0534 0.98 655 or older 339/2782 (14-8) 277/2825 (12-5) 119 (10-21-40) 0.0284 300 mass index		PCI	CABG				Interaction
Male 387/4380 (10.7) 318/4394 (8.8) Image 120 (10-31-39) 0.0131 0.82 Female 123 (10-71-57) 0.0854 0.0131 0.0231 0.0231 0.0231 Ge 300/2371 (8:0) 160/2340 (6:4) Image 123 (10-01-150) 0.0534 0.0334 0.0334 G5 0.012/371 (8:0) 160/2340 (6:4) Image 120 (10-01-140) 0.024 0.0155 G40 393/73958 (11-2) 304/3953 (9:4) Image 120 (10-01-140) 0.017 0.017 S00 more 148/1548 (12.1) 106/1558 (8:6) Image 1135 (10-01-140) 0.027 0.025 No 137/13580 (12.2) 32/3913 (10-6) Image 1136 (10-01-140) 0.027 0.026 Vest 364/3982 (11-0) 288/3862 (9:1) 1337 (10-01-76) 0.027 0.027 0.026 No 278/2215 (15-7) 185/2171 (10-7) Image 124 (10-01-150) 0.027 0.026 No 288/32 (130) 252/3594 (8:4) 123 (10-61-76) 0.0452 0.076 0.076 No 218/2070 (10-3) 364/4724 (8:7)	Subgroups	PU	LABG		HR (95% CI)	p-value	p-value
Female 152/1373 (12:7) 119/1371 (10:6) 1.23 (10:7): 50 0.0854 Age at Baseline 265 200/2971 (8:0) 160/2940 (6:4) 1.23 (10:01-151) 0.0534 0.98 G5 or older 339/2782 (14:8) 277/2825 (12:5) 1.19 (10:2-1:40) 0.0156 0.43 Sody mass index 1.23 (10:01-151) 0.0156 0.43 0.057 0.43 G3 or one or 148/1548 (12:1) 106/1558 (8:6) 1.35 (10:5-1:73) 0.057 0.25 No 145/1859 (9:1) 103/1835 (6:6) 1.37 (10:6-1:76) 0.014 0.0527 0.25 No 145/1859 (9:1) 103/1835 (6:6) 1.19 (10:2-1:39) 0.0272 0.76 No 123 (10:6) 1.19 (10:2-1:39) 0.027 0.76 No 127/1744 (11:6) 185/1271 (10:7) 1.24 (10:0-1:34) 0.052 0.057 No 261/3538 (8:7) 252/3594 (8:4) 1.02 (0.86:1-21) 0.81 0.0051 0.0052 0.057 Version 75/242 (20:7) 58/440 (16:0) 1.21 (10:7) 1.21 (10:7) 0.0052 0.97 0.0652 0.97 No 1	Sex						
sqe at Baseline 123 (1-00-1-51) 0.0534 0.98 65 or older 339/782 (148) 277/2825 (12-5) 19 (102-1-40) 0.0284 0.0284 300 more 148/1548 (12-1) 0.06/1558 (8-6) 1-00 (1-04-1-40) 0.0155 0.43 30 or more 148/1548 (12-1) 106/1558 (8-6) 1-00 (1-04-1-40) 0.0155 0.43 4ypertension	Male	387/4380 (10-7)	318/4394 (8.8)	. ⊢ ← −1	1.20 (1.03-1.39)	0.0181	0.82
< 65	Female	152/1373 (12-7)	119/1371 (10.6)	H +I	1.23 (0.97-1.57)	0.0854	
65 or older 393/2782 (14.8) 277/2825 (12.5) 119 (102.140) 0.0284 Sody mass index 304/3953 (9.4) 1-20 (104.140) 0.015 0.43 30 or more 148/1548 (12.2) 304/3953 (9.4) 1-20 (104.140) 0.015 0.43 30 or more 148/1548 (12.2) 332/3913 (10.6) 1-16 (1.00-1.34) 0.0527 0.254 No 145/1859 (9.1) 103/1835 (6.6) 1-19 (102.1-38) 0.027 0.76 Hypertension 119 (102.1-30) 0.027 0.76 Yes 054/3982 (11.0) 288/3862 (9.1) 1.19 (102.1-38) 0.027 0.76 No 124 (120.17) 148/1873 (9.5) 1.24 (120.17) 0.001 0.0077 Poison 276/2215 (15.7) 125/2171 (10.7) 1.24 (120.17) 0.001 0.001 No 261/353 (8.7) 25/354 (8.4) 1.21 (105.1-38) 0.002 0.001 Prior mozordial infort/er 135 (105.1) 1.24 (100.17) 1.24 (100.1-30) 0.004 0.001 Yes 183/1438 (14.2) 16/1471 (11.6) 1.22 (103.1-140) 0.018 0.0186 0.018 0.018	Age at Baseline						
Sody mass index < 30	< 65	200/2971 (8.0)	160/2940 (6-4)	⊢ •−1	1.23 (1.00-1.51)	0.0534	0.98
< 30	65 or older	339/2782 (14-8)	277/2825 (12.5)	<u>¦+</u> i	1.19 (1.02-1.40)	0.0284	
30 or more 148/1548 (12-1) 106/1558 (8-6) 1-35 (105-173) 0.0179 ivpertension 126 (100-1-34) 0.0527 0.25 No 145/1859 (9-1) 0.30 (133 (6-6) 1-37 (106-17-6) 0.0144 ivperlipidemia 129 (100-1-34) 0.0527 0.25 No 173/1744 (11-6) 288/3862 (9-1) 1-9 (102-1-39) 0.0272 0.76 No 173/1744 (11-6) 148/1873 (9-5) 1-24 (100-155) 0.0527 0.0077 No 21/3538 (8.7) 252/3594 (8-4) 1-9 1-02 (086-121) 0.81 eripheral vascular discurst 1-94 (120-1-74) 0.0001 0.0077 No 21/3538 (8.7) 252/3594 (8-4) 1-9 1-02 (086-121) 0.81 eripheral vascular discurst 1-94 (120-1-74) 0.0001 0.0077 No 318/4734 (10-6) 346/4724 (8.7) 1-94 (120-1-139) 0.00869 0.66 No 318/3700 (10-2) 257/3739 (8-4) 1-94 (1097-150) 0.0852 0.97 No 318/300 (10-2) 257/3739 (8-4) 1-94 (1097-150) 0.0852 0.97 No <td>Body mass index</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>	Body mass index						
Augertension Yes 391/3880 (12-2) 332/3913 (10-6) I -16 (1-00-1-34) 0.0527 0.25 No 145/1859 (9-1) 103/1835 (6-6) I -19 (1-02-1-39) 0.0272 0.76 typertension 787 364/3982 (11-0) 288/3862 (9-1) I -19 (1-02-1-39) 0.0272 0.76 No 173/1744 (1-6) 148/1873 (9-5) I -24 (1-00-1-50) 0.0021 0.0077 Objects mellitus Yes 278/2215 (15-7) 185/2171 (10-7) I -4 1-44 (1-20-1-74) 0.0001 0.0077 No 261/3538 (8-7) 252/3594 (8-4) I -4 1-35 (0-96-1-90) 0.0869 0.666 Performational state 75/424 (20-7) 58/440 (16-0) I -4 1-35 (0-96-1-90) 0.0869 0.667 No 318/4734 (1-6) 346/4724 (8-7) I -4 1-32 (1-05-1-39) 0.0014 Prior myocardial infartional state 313/438 (14-2) 146/1417 (11-6) I -4 1-21 (1-97-150) 0.6852 0.977 No 318/3700 (10-2) 25/3739 (8-4) I -4 I -44 (1-08-1430) 0.0182 0.971 <	< 30	373/3958 (11-2)	304/3953 (9-4)	ii	1.20 (1.04-1.40)	0.0156	0.43
Yes 391/380 (12-2) 332/3913 (10-6) 1-16 (1-00-1:34) 0.0527 0.25 No 145/1859 (9-1) 103/1835 (6-6) 1-37 (10-6-1:76) 0.0144 typerlipidemia 1-19 (1-02-1:39) 0.0272 0.76 No 173/1744 (11-6) 148/1873 (9-5) 1-19 (1-02-1:39) 0.0272 0.76 No 173/1744 (11-6) 148/1873 (9-5) 1-24 (1-00-1:55) 0.0527 0.0077 No 2178/2215 (15-7) 185/2171 (10-7) 1-44 (1-20-1:49) 0.0077 0.0077 No 261/3538 (8:7) 252/3594 (8-4) 1-02 (0.86-1:21) 0.81 0.0077 No 248/4734 (10-6) 346/4724 (8:7) 1-35 (0-96-1:90) 0.0869 0.666 No 428/4734 (10-6) 346/4724 (8:7) 1-21 (0-97-1:50) 0.0852 0.97 No 318/3100 (10-2) 257/3739 (8:4) 1-22 (1-03-1:44) 0.0180 0.0180 eft ventricular ejection Fratom 1-14 (0-98-1:32) 0.097 0.65 0.052 0.97 0.012 0.91 0.21 20% 356/4447 (9-6) 311/4597 (8:3) 1-21 (0-97-1:54)	30 or more	148/1548 (12-1)	106/1558 (8-6)	¦⊢I	1.35 (1.05-1.73)	0.0179	
No 145/1859 (9·1) 103/1833 (6·6) 1-37 (106·1.76) 0.0144 Hyperlipidemia 119 (1.02-1.39) 0.0272 0.76 No 173/1744 (11-6) 148/1873 (9·5) 124 (1.00-1.55) 0.0527 Diabetes mellitus 124 (1.00-1.55) 0.0527 0.007N No 251/3538 (8.7) 252/3594 (8.4) 102 (0.86-1.21) 0.81 Peripheral vascular disease 124 (1.00-1.55) 0.0089 0.666 No 428/4734 (10-6) 346/4724 (8.7) 1.35 (0.96-1.90) 0.0869 0.666 No 428/4734 (10-6) 346/4724 (8.7) 1.21 (1.05-1.39) 0.0094 0.0071 Prior myocardial infarction 1.22 (1.03-1.44) 0.0180 0.0180 0.977 No 318/3700 (10.2) 257/3739 (8.4) 1.14 (1.08-1.44) 0.0122 0.971 No 318/4300 (10.2) 257/3739 (8.4) 1.14 (1.08-1.44) 0.0122 0.971 S0 356/4447 (9.6) 311/4597 (8.3) 1.14 (0.98-1.32) 0.0974 0.655 30-49% 132/807 (19-3) 96/779 (15-1) 1.44 (1.08-1.44) 0.0122 0.971	Hypertension			1			
hyperlipidemia Yes 364/3982 (11-0) 288/3862 (9-1) 119 (1-02-1-39) 0.0272 0.76 No 173/1744 (11-6) 148/1873 (9-5) 124 (1-00-1-55) 0.0527 Diabetes mellitus 124 (1-00-1-53) 0.0071 0.0071 No 213/1744 (11-6) 148/1873 (9-5) 144 (1-20-1-74) 0.0001 0.0077 No 261/3538 (8-7) 252/3594 (8-4) 102 (0-86-121) 0.81 0.0071 Vers 75/424 (20-7) 58/440 (16-0) 1-35 (0-96-1-90) 0.0869 0.666 No 428/4734 (10-6) 346/4724 (8-7) 1-21 (0-97-1-50) 0.0852 0.977 Ves 183/1438 (14-2) 146/1417 (11-6) 1-21 (0-97-1-50) 0.0852 0.977 No 318/3700 (10-2) 257/3739 (8-4) 1-44 1-21 (0-97-1-50) 0.0852 0.977 No 318/3700 (10-2) 257/3739 (8-4) 1-44 (1-48-184) 0.0122 0.974 0.655 30-49% 312/807 (19-3) 96/779 (15-1) 1-44 (1-08-184) 0.912 0.216 sesion complexity SYNTAX score 0-22 105/1533 (8-1) <td>Yes</td> <td>391/3880 (12-2)</td> <td>332/3913 (10.6)</td> <td>i→i</td> <td>1.16 (1.00-1.34)</td> <td>0.0527</td> <td>0.22</td>	Yes	391/3880 (12-2)	332/3913 (10.6)	i→i	1.16 (1.00-1.34)	0.0527	0.22
Yes 364/3982 (11-0) 288/3862 (9-1) 11-19 (10-21-39) 0-0272 0-76 No 173/1744 (11-6) 148/1873 (9-5) 124 (1-00-1-55) 0-0527 Diabetes mellitus 1-24 (1-00-1-55) 0-0527 0-0071 No 261/3538 (8-7) 252/3594 (8-4) 1-04 1-24 (1-00-1-55) 0-0071 No 261/3538 (8-7) 252/3594 (8-4) 1-04 1-02 (0-86-1-21) 0-81 Peripheral vascular disease	No	145/1859 (9.1)	103/1835 (6-6)	·	1.37 (1.06-1.76)	0.0144	
No 173/1744 (11-6) 148/1873 (9-5) 1-24 (1-00-1-55) 0-0527 Diabetes mellitus	Hyperlipidemia			ł			
Diabetes mellitus Yes 278/2215 (15-7) 185/2171 (10-7) Image: colspan="2">1.44 (1-20-1-74) 0.0001 0.0077 No 261/3538 (8-7) 252/3594 (8.4) Image: colspan="2">1.02 (0.86-1-21) 0.81 Peripheral vascular disease 75/424 (20-7) 58/440 (16-0) Image: colspan="2">1.35 (0.96-1-90) 0.0869 0.66 No 428/4734 (10-6) 346/4724 (8-7) Image: colspan="2">Image: colspan="2" Colspan="2	Yes	364/3982 (11.0)	288/3862 (9.1)	¦+1	1.19 (1.02-1.39)	0.0272	0.76
Yes 278/2215 (15-7) 185/2171 (10-7) 144 (120-174) 0-0001 0-0077 No 261/3538 (8-7) 252/3594 (8.4) 102 (0-86-1-21) 0.81 Peripheral vascular diseuterererererererererererererererererere	No	173/1744 (11-6)	148/1873 (9.5)	⊢ ⊷−1	1.24 (1.00-1.55)	0.0527	
No 261/3538 (8-7) 252/3594 (8-4) Image: Constraint of the second s	Diabetes mellitus						
Peripheral vascular disease Yes 75/424 (20-7) 58/440 (16-0) No 428/4734 (10-6) 346/4724 (8-7) Prior myocardial infarction 1:21 (10-51-39) 0.0094 Yes 183/1438 (14-2) 146/1417 (11-6) 1-21 (0-97-1-50) 0.0852 0-97 No 318/3700 (10-2) 257/3739 (8-4) 1-22 (1-03-1-44) 0.0180 0.0180 eft ventricular ejection fraction 1-14 (0-98-1-32) 0-0974 0-65 30-49% 356/4447 (9-6) 311/4597 (8-3) 1-4 1-14 (0-98-1-32) 0-0974 0-65 30-49% 132/807 (19-3) 96/779 (15-1) 1-41 (1-08-1-84) 0-0122 - <30%	Yes	278/2215 (15-7)	185/2171 (10.7)	⊢ ⊷−1	1.44 (1.20-1.74)	0.0001	0.0077
Yes 75/424 (20.7) 58/440 (16-0) 1.35 (0.96-1:90) 0.0869 0.66 No 428/4734 (10-6) 346/4724 (8-7) 1.21 (1.05-1:39) 0.0094 Prior myocardial infarction 1.21 (0.97-1:50) 0.0852 0.97 No 318/3700 (10-2) 257/3739 (8-4) 1.22 (1.03-1:44) 0.0180 eft ventricular ejection 556/4447 (9-6) 311/4597 (8-3) 1.14 (0.98-1:32) 0.097 0.655 30-49% 356/4447 (9-6) 311/4597 (8-3) 1.14 (1.08-1:84) 0.0122 0.051 <300	No	261/3538 (8.7)	252/3594 (8-4)	⊢ •	1.02 (0.86-1.21)	0.81	
No 428/4734 (10-6) 346/4724 (8-7) I-21 (105-1-39) 0-0094 Prior myocardial infar-time 121 (0-97-1-50) 0-0852 0-97 No 318/3700 (10-2) 257/3739 (8-4) 1-22 (10-97-1-50) 0-0852 0-97 No 318/3700 (10-2) 257/3739 (8-4) 1-22 (10-97-1-50) 0-0852 0-97 eft ventricular ejection raction 1-24 (10-98-1-32) 0-0074 0-65 30-49% 312/807 (19-3) 96/779 (15-1) 1-41 (10-81-84) 0-0122 <30%	Peripheral vascular d	isease		i			
Prior myocardial infarction Yes 183/1438 (14-2) 146/1417 (11-6) No 318/3700 (10-2) 257/3739 (8-4) .eft ventricular ejection raction ≥50% 356/4447 (9-6) 311/4597 (8-3) .ady 132/807 (19-3) 96/779 (15-1) .ady 132/807 (19-3) 96/779 (15-1) .ady 13/49 (57-3) 16/54 (34-4) .ady 18/49 (57-3) 16/54 (34-4) .ady 122 (10-71-134) 0-91 .ady 100/1585 (8-1) 1-02 (0-77-134) 0-91 .yntAx score 23-32 163/1677 (12-4) 122/1545 (10-9) 1-52 (1-15-202) 0-0029 .yntAx score >33 117/871 (16-5) 83/927 (11-6) 1-52 (1-15-202) 0-0029 .uss .uss .uss .uss .uss .uss .uss .uss .uss .uss .uss .uss .uss .uss .uss .uss .uss .uss .uss .uss .uss .uss .uss .uss .uss .uss .uss .uss .uss .uss	Yes	75/424 (20-7)	58/440 (16.0)	+	1.35 (0.96-1.90)	0.0869	0.66
Yes 183/1438 (14-2) 146/1417 (11-6) 1-21 (0-97-1-50) 0.0852 0-97 No 318/3700 (10-2) 257/3739 (8-4) 1-22 (1-03-1-44) 0-0180 eft ventricular ejection fraction 1-22 (1-03-1-44) 0-0180 0-0974 0-65 30-49% 356/4447 (9-6) 311/4597 (8-3) 1-44 (1-08-1-32) 0-0974 0-65 30-49% 132/807 (19-3) 96/779 (15-1) 1-44 (1-08-1-84) 0-0122 0-021 <30%	No	428/4734 (10.6)	346/4724 (8.7)	¦⊷⊷i	1.21 (1.05-1.39)	0.0094	
No 318/3700 (10·2) 257/3739 (8·4) Image: constraint of the second	Prior myocardial infa	rction					
eff ventricular ejection s36/4447 (9-6) 311/4597 (8-3) 1-14 (0-98-1-32) 0-0974 0-65 30-49% 132/807 (19-3) 96/779 (15-1) 1-41 (1-08-1-84) 0-0122 <30%	Yes	183/1438 (14-2)	146/1417 (11.6)	i —	1.21 (0.97-1.50)	0.0852	0.97
\$250% 356/4477 (9-6) 311/4597 (8-3) 1-14 (0-98-1-32) 0-0974 0-65 30-49% 132/807 (19-3) 96/779 (15-1) 1-41 (1-08-1-84) 0-0122 0-074 0-65 <30%	No	318/3700 (10-2)	257/3739 (8-4)	·	1.22 (1.03-1.44)	0.0180	
30-49% 132/807 (19·3) 96/779 (15·1) 1-41 (1·08-1·84) 0-0122 <30%	Left ventricular ejecti	on fraction		1			
< <tr> <30% 18/49 (57·3) 16/54 (34·4) 1-25 (0-64-2·46) 0-52 esion complexity 1-02 (0-77-1·34) 0-91 0-21 SYNTAX score 0-22 105/1533 (8·8) 1000/1585 (8·1) 1-02 (0-77-1·34) 0-91 0-21 SYNTAX score 23-32 163/1677 (12·4) 122/1545 (10·9) 1-4 1-52 (1·15-2·02) 0-0029 SYNTAX score >33 117/871 (16·5) 83/927 (11·6) 1-2 3 1-52 (1·15-2·02) 0-0029 0.5 1 2 3 3 1-2 3 1-52 (1·15-2·02) 0-0029</tr>	≥50%	356/4447 (9.6)	311/4597 (8·3)	l ¦ ♦ I	1.14 (0.98-1.32)	0.0974	0.65
Lesion complexity SYNTAX score 0-22 105/1533 (8-8) 100/1585 (8-1) 1-02 (0-77-1-34) 0-91 0-21 SYNTAX score 23-32 163/1677 (12-4) 122/1545 (10-9) 1-20 (0-94-1-51) 0-14 SYNTAX score >33 117/871 (16-5) 83/927 (11-6) 1-52 (1-15-2-02) 0-0029 0.5 1 2 3 Favors PCI HR Favors CABG	30-49%	132/807 (19.3)	96/779 (15.1)		1.41 (1.08-1.84)	0.0122	
SYNTAX score 0-22 105/1533 (8-8) 100/1585 (8-1) 1-02 (0-77-1-34) 0-91 0-21 SYNTAX score 23-32 163/1677 (12-4) 122/1545 (10-9) 1-20 (0-94-1-51) 0-14 SYNTAX score >33 117/871 (16-5) 83/927 (11-6) 1-52 (1-15-2-02) 0-0029 0.5 1 2 3 Favors PCI HR	<30%	18/49 (57-3)	16/54 (34-4)	⊢––––––	1.25 (0.64-2.46)	0.52	
SYNTAX score 23-32 163/1677 (12-4) 122/1545 (10-9) 1 1 1-20 (0-94-1-51) 0-14 SYNTAX score >33 117/871 (16-5) 83/927 (11-6) 1 1-52 (1-15-2-02) 0-0029 0.5 1 2 3 Favors PCI HR Favors CABG	Lesion complexity			i			
SYNTAX score >33 117/871 (16-5) 83/927 (11-6) 1-52 (1-15-2-02) 0-0029 0.5 1 2 3 Favors PCI HR Favors CABG	SYNTAX score 0-22	105/1533 (8.8)	100/1585 (8.1)	⊢ ⊢	1.02 (0.77-1.34)	0.91	0.21
05 1 2 3 Favors PCI HR Favors CABG	SYNTAX score 23-32	163/1677 (12-4)	122/1545 (10.9)	ı ¦ →→→	1.20 (0.94-1.51)	0-14	
Favors PCI HR Favors CABG	SYNTAX score >33	117/871 (16.5)	83/927 (11.6)	·	1.52 (1.15-2.02)	0.0029	
Favors PCI HR Favors CABG			0.5	1 2	7		
(95%CI)							
(00/00/)				(95%CI)			

ct2017



Diabetes No






t2017




Stroke after CABG and PCI








Stroke after CABG or PCI Landmark analysis



2017



Stroke CABG and PCI Diabetes versus non-Diabetes



t2017



Conclusions pooled analysis of 11,518 patients from 11 randomized trials

Largest analysis of patients randomly assigned to PCI with stents or CABG

Mortality significantly lower with CABG in patients with multivessel disease and diabetes, and high coronary lesion complexity

Patients with left main disease and lower coronary lesion complexity have comparable survival with PCI and CABG

Stroke risk is higher in patients with diabetes undergoing CABG



